TGA probes reports of rare neurological disorder following COVID-19 vax
It follows warnings from the European medicines watchdog, which recommended updating Vaxzevria's product information
The TGA is investigating reports of suspected transverse myelitis among recipients of AstraZeneca’s COVID-19 vaccine following warnings of the potential safety signal from its European counterpart.
As of 16 January, the regulator had received 16 reports of the rare neurological disorder from nearly 14 million doses of the viral-vector vaccine administered to date.
Transverse myelitis can have multiple causes including infection — particularly viral infection — and underlying demyelinating disease such as MS and
